As filed with the Securities and Exchange Commission on January 12, 2022
Registration No. 333-261504
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective Amendment No. 1
to
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
INTERPACE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware | 3841 | 22-2919486 | ||
(State or other jurisdiction of incorporation) | (Primary Standard Industrial Classification Code Number) | (IRS Employer Identification No.) |
Morris Corporate Center 1, Building C
300 Interpace Parkway
Parsippany, New Jersey 07054
(855) 776-6419
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Thomas W. Burnell
President, Chief Executive Officer and Director
Morris Corporate Center 1, Building C
300 Interpace Parkway
Parsippany, New Jersey 07054
(855) 776-6419
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Merrill M. Kraines, Esq.
Troutman Pepper Hamilton Sanders LLP
875 Third Avenue
New York, NY 10022
Tel: (212) 808-2711
Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-261504
This Registration Statement shall become effective upon filing in accordance with Rule 462(d) under the Securities Act of 1933.
EXPLANATORY NOTE
This Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-261504) is filed pursuant to Rule 462(d) solely to add an updated Exhibit 5.1 with respect to such Registration Statement.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 16. Exhibits and Financial Statement Schedules
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Post-Effective No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Parsippany, State of New Jersey, on January 12, 2022.
INTERPACE BIOSCIENCES, INC. | ||
By: | /s/ Thomas W. Burnell | |
Thomas W. Burnell | ||
President, Chief Executive Officer and Director (Principal Executive Officer) |
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated below.
/s/ Thomas W. Burnell | President, Chief Executive Officer and Director | January 12, 2022 | ||
Thomas W. Burnell | (Principal Executive Officer) | |||
/s/ Thomas Freeburg | Chief Financial Officer and Treasurer | January 12, 2022 | ||
Thomas Freeburg | (Principal Financial and Accounting Officer) | |||
* | Director | January 12, 2022 | ||
Stephen J. Sullivan | ||||
* | Director | January 12, 2022 | ||
Joseph Keegan | ||||
* | Director | January 12, 2022 | ||
Eric Lev | ||||
* | Chairman of the Board of Directors | January 12, 2022 | ||
Robert Gorman | ||||
* | Director | January 12, 2022 | ||
Edward Chan | ||||
* | Director | January 12, 2022 | ||
Fortunato Ron Rocca |
*By: | /s/ Thomas W. Burnell | |
Thomas W. Burnell | ||
Attorney-in-Fact |